Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …
populations have an underlying predisposition to deficient insulin secretion, which has a key …
Racial, ethnic and regional differences in the effect of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and …
Objectives The cardiorenal protective effects of sodium–glucose co-transporter 2 inhibitors
(SGLT2-Is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) across racial and …
(SGLT2-Is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) across racial and …
[HTML][HTML] Management of metabolic-associated fatty liver disease: The diabetology perspective
MS Jeeyavudeen, SKA Khan, S Fouda… - World Journal of …, 2023 - ncbi.nlm.nih.gov
The metabolic syndrome as a consequence of the obesity pandemic resulted in a
substantial increase in the prevalence of metabolic-associated fatty live disease (MAFLD) …
substantial increase in the prevalence of metabolic-associated fatty live disease (MAFLD) …
Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: implications, management, and future directions: a scientific …
Asian American individuals make up the fastest growing racial and ethnic group in the
United States. Despite the substantial variability that exists in type 2 diabetes and …
United States. Despite the substantial variability that exists in type 2 diabetes and …
Expert opinion: optimum clinical approach to combination-use of SGLT2i+ DPP4i in the Indian diabetes setting
M Chadha, AK Das, P Deb, KK Gangopadhyay… - Diabetes Therapy, 2022 - Springer
Abstract The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized
for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio …
for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio …
Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas
OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes,
remain widely prescribed today. However, there exists significant variability in glycemic …
remain widely prescribed today. However, there exists significant variability in glycemic …
Incidence and pathophysiology of diabetes in South Asian adults living in India and Pakistan compared with US blacks and whites
Introduction We compared diabetes incidence in South Asians aged≥ 45 years in urban
India (Chennai and Delhi) and Pakistan (Karachi), two low-income and middle-income …
India (Chennai and Delhi) and Pakistan (Karachi), two low-income and middle-income …
Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
YH Zeng, SC Liu, CC Lee, FJ Sun, JJ Liu - Scientific Reports, 2022 - nature.com
Insulin therapy often increases body weight and leads to visceral fat accumulation.
Progression in diabetes is also associated with accelerated loss of muscle mass. Little is …
Progression in diabetes is also associated with accelerated loss of muscle mass. Little is …
Clinical practice guidelines for the management of type 2 diabetes in south Asia: a systematic review
A Pervez, A Ahmer, O Mahmud, RS Martins… - Diabetes & Metabolic …, 2024 - Elsevier
Abstract Background Clinical practice guidelines (CPGs) are a helpful tool for the evidence-
based management of Type 2 Diabetes Mellitus (T2D). The aim of this systematic review …
based management of Type 2 Diabetes Mellitus (T2D). The aim of this systematic review …
Glycemic variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes mellitus: a systematic review and meta-analysis
H Lee, S Park, EY Kim - Journal of Clinical Medicine, 2021 - mdpi.com
To investigate the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-
like peptide 1 (GLP-1) agonists on glycemic variability (GV), the mean amplitude of glucose …
like peptide 1 (GLP-1) agonists on glycemic variability (GV), the mean amplitude of glucose …